TITLE

BIO response to December editorial

AUTHOR(S)
Greenwood, Jim
PUB. DATE
February 2014
SOURCE
Nature Biotechnology;Feb2014, Vol. 32 Issue 2, p131
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A letter to the editor in response to the article which discusses the role of Biotechnology Industry Organization in the U.S. in establishing the pathway for the approval of biosimilars and also provide information on treating the biosimilars as generic drugs.
ACCESSION #
94346028

 

Related Articles

  • Exclusivity Issue Needlessly Thwarting Biogenerics Debate. Thiel, Karl // BioWorld Today;7/1/2009, Vol. 20 Issue 125, p1 

    The article reports on the issues surrounding the exclusivity of the biogenerics legislation in the U.S. It notes the contention of the Biotechnology Industry Organization (BIO) on the number of years of data exclusivity an innovator product would enjoy before a follow-on products could be...

  • More States Are Saying No To Biosimilar Safeguards. Serebrov, Mari // BioWorld Today;5/8/2013, Vol. 24 Issue 88, p1 

    This article discusses the move of several U.S. states, which include Colorado, Florida and Indiana, to create legislation requiring notification and recordkeeping if a pharmacy substitutes biosimilar drugs for the prescribed biologic medication. It is inferred that the bill was based on the...

  • State Legislatures Become Battlegrounds for Biosimilars. Van Arnum, Patricia // BioPharm International;May2013, Vol. 26 Issue 5, p9 

    The article offers information on the legislative bill related to the dispensing of biosimilars drugs in the U.S. which has been rejected by legislative body of several states including Maryland, Arizona and Mississippi. It states that the rejection of the bill favors the concerns of the Generic...

  • Large drugs outdo small. Hughes, Bethan // Nature Biotechnology;Apr2011, Vol. 29 Issue 4, p296 

    The article reports an analyses of the approval rates of 4,275 drugs in development from 2003 to 2010 by Biotechnology Industry Organiation (BIO) and BioMedTracker of San Diego, California presented at the 13th Annual Biotechnology Industry Organization Chief Executive and Investor Conference...

  • Can There Be Abbreviated Applications, Generics, or Follow-On Products? Webster, Christopher; Copmann, Thomas; Garnick, Robert; Green, James; Hayes, Mark; Landis, John; Lubiniecki, Anthony; Murano, Genesio; Seamon, Kenneth; Zezza, Diane; Woollett, Gillian R. // BioPharm International;Jul2003, Vol. 16 Issue 7, p28 

    Presents questions and answers advisory on generic biologics. Definition of biologic; Meaning of generic biologics; Importance of follow-on biologics to the innovator industry.

  • Biosimilars Market Presents Tough Challenges.  // Chain Drug Review;11/19/2012, Vol. 34 Issue 20, p61 

    The article presents the views of Claudio Albrecht, chief executive officer of Actavis Group hf, on biosimilars market related issues surrounding the companies that create biotech drugs and the generic drug industry.

  • Biosimilars pit industry reps against each other. DeArment, Alaric // Drug Store News;8/10/2009, Vol. 31 Issue 9, p34 

    The article reports on the debate between biotechnology industry and generic drug industry about biosimilars pits in the U.S. It mentions that both industries were well represented by the Biotechnology Industry Organization and the Generic Pharmaceutical Association. These organizations support...

  • Prescribing Caution for Biosimilars. Greenwood, James C. // Pharmaceutical Technology;Apr2013, Vol. 37 Issue 4, p14 

    The author reflects on the policies regarding drug substitution and its importance in healthcare and chronic disease management. The author says that Biotechnology Industry Organization (BIO) has developed five principles on drug substitution including the Food and Drug Administration (FDA)...

  • Biosimilars could save $US billions.  // PharmacoEconomics & Outcomes News;Nov2014, Vol. 716 Issue 1, p1 

    The article discusses a report from nonprofit research institute Rand Corp., which examines the cost savings potential of biosimilars or generic versions of biologicals used in treating various medical conditions until 2024 in the U.S.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics